Asthma Induction by Dendritic Cells and Th2 Cells

树突状细胞和 Th2 细胞诱导哮喘

基本信息

  • 批准号:
    7152919
  • 负责人:
  • 金额:
    $ 32.53万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2004
  • 资助国家:
    美国
  • 起止时间:
    2004-01-01 至 2008-11-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Asthma is an important disease that afflicts 5% of the general population. Atopic asthma is caused by biased-T helper 2 (Th2) responses to allergens. In a mouse model, mice primed intratracheally with Ag-pulsed dendritic cells and challenged with Ag developed airway hyperresponsiveness, and lung eosinophilia and inflammation. Lungs have a more Th2-biased environment and primed T cells seem to divide faster in the lungs than lymph nodes in Ag-challenged mice, although the lymph node is believed to be the site of T cell activation and development. In this study, lung DC have been found to be composed of multiple subset. Studies on DC migration suggest that secondary lymphoid chemokine (SLC/CCL21) may be a key chemokine for DC migration to draining LN. In the lung but not lymph nodes of lung-immunized mice, large numbers of interferon-gamma-producing CD8+ T cells (Tc1) were present, resulting in a more Th2-baised environment in the lungs. These results support the hypothesis that: "a DC subset that presents antigen in lungs and mediates a Th2-biased response occurs in lungs. For T lymphocyte and DC migration to lymph nodes, SLC is a major mediator. Because Th1 and Tc1 cell numbers are very low in the inflammatory lungs, activated T cells readily develop into Th2 cells." In this proposal, experiments are designed to support this hypothesis. The aims consist of: (1) the isolation and functional studies of DC subsets in lungs; (2) the studies of CCR7/SLC interaction as a key chemokine receptor/chemokine interaction for lung DC and T cell migration to lymph nodes. The roles of other important candidate chemokine receptors such as CCR2 in mediating DC migration will also be examined; and (3) the studies of the migration of IFN-gamma-producing CD8+ T cells away from lungs during asthma pathogenesis. These studies will clarify the roles of DC and CD8+ T cells in the biased-Th2 lung response in asthma and provide a novel mechanism for Th2-biased responses during asthma pathogenesis. The results may provide additional therapeutic strategies in asthma by the interference of SLC functions and by regulating the migration of DC, Th1, and IFN-gamma-producing CD8+ T cells.
描述(由申请人提供):哮喘是一种重要的疾病,困扰着5%的普通人群。特应性哮喘是由偏倚t辅助2 (Th2)对过敏原的反应引起的。在小鼠模型中,小鼠气管内注入银脉冲树突状细胞并受到银刺激后,出现气道高反应性、肺嗜酸性粒细胞增多和炎症。肺部有一个更偏向于th2的环境,在ag挑战小鼠中,启动T细胞似乎比淋巴结分裂得更快,尽管淋巴结被认为是T细胞激活和发育的地方。本研究发现肺DC由多个亚群组成。有关DC迁移的研究表明,次级淋巴样趋化因子(SLC/CCL21)可能是DC迁移至引流LN的关键趋化因子。在肺免疫小鼠的肺部而不是淋巴结中,存在大量产生干扰素- γ的CD8+ T细胞(Tc1),导致肺部更以th2为基础的环境。这些结果支持以下假设:“DC亚群在肺中呈现抗原并介导th2偏倚反应发生在肺中。对于T淋巴细胞和DC向淋巴结的迁移,SLC是一个主要的中介。因为炎性肺中Th1和Tc1细胞数量非常低,激活的T细胞很容易发育成Th2细胞。”在这个提议中,实验被设计来支持这个假设。目的包括:(1)肺中DC亚群的分离和功能研究;(2) CCR7/SLC相互作用作为肺DC和T细胞向淋巴结迁移的关键趋化因子受体/趋化因子相互作用研究。其他重要的候选趋化因子受体如CCR2在介导DC迁移中的作用也将被检查;(3)哮喘发病过程中产生ifn - γ的CD8+ T细胞向肺外迁移的研究。这些研究将阐明DC和CD8+ T细胞在哮喘偏置th2肺反应中的作用,并为哮喘发病过程中th2偏置反应提供新的机制。该结果可能通过干扰SLC功能和调节DC、Th1和产生ifn - γ的CD8+ T细胞的迁移,为哮喘提供额外的治疗策略。

项目成果

期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Sun-Sang Joseph Sung其他文献

Sun-Sang Joseph Sung的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Sun-Sang Joseph Sung', 18)}}的其他基金

NLRP3 Inflammasome Activation, T Follicular Helper Cells and Autoimmunity
NLRP3 炎症小体激活、滤泡辅助 T 细胞和自身免疫
  • 批准号:
    10686392
  • 财政年份:
    2020
  • 资助金额:
    $ 32.53万
  • 项目类别:
NLRP3 Inflammasome Activation, T Follicular Helper Cells and Autoimmunity
NLRP3 炎症小体激活、滤泡辅助 T 细胞和自身免疫
  • 批准号:
    10459502
  • 财政年份:
    2020
  • 资助金额:
    $ 32.53万
  • 项目类别:
Infections, Microbiome and HLA-DR in the Induction of Lupus Related Auto-antibodies
感染、微生物组和 HLA-DR 在狼疮相关自身抗体诱导中的作用
  • 批准号:
    10443777
  • 财政年份:
    2018
  • 资助金额:
    $ 32.53万
  • 项目类别:
Histology
组织学
  • 批准号:
    7746112
  • 财政年份:
    2009
  • 资助金额:
    $ 32.53万
  • 项目类别:
CD103+ Dendritic Cells and Regulatory T cells in Food Allergy
食物过敏中的 CD103 树突状细胞和调节性 T 细胞
  • 批准号:
    7846695
  • 财政年份:
    2009
  • 资助金额:
    $ 32.53万
  • 项目类别:
CD103+ Dendritic Cells and Regulatory T cells in Food Allergy
食物过敏中的 CD103 树突状细胞和调节性 T 细胞
  • 批准号:
    7638423
  • 财政年份:
    2008
  • 资助金额:
    $ 32.53万
  • 项目类别:
CD103+ Dendritic Cells and Regulatory T cells in Food Allergy
食物过敏中的 CD103 树突状细胞和调节性 T 细胞
  • 批准号:
    7539730
  • 财政年份:
    2008
  • 资助金额:
    $ 32.53万
  • 项目类别:
Asthma Induction by Dendritic Cells and Th2 Cells
树突状细胞和 Th2 细胞诱导哮喘
  • 批准号:
    6841211
  • 财政年份:
    2004
  • 资助金额:
    $ 32.53万
  • 项目类别:
Asthma Induction by Dendritic Cells and Th2 Cells
树突状细胞和 Th2 细胞诱导哮喘
  • 批准号:
    6987170
  • 财政年份:
    2004
  • 资助金额:
    $ 32.53万
  • 项目类别:
Asthma Induction by Dendritic Cells and Th2 Cells
树突状细胞和 Th2 细胞诱导哮喘
  • 批准号:
    6724710
  • 财政年份:
    2004
  • 资助金额:
    $ 32.53万
  • 项目类别:

相似海外基金

Time to ATTAC: Adoptive Transfer of T cells Against gp100+ Cells to treat LAM
ATTAC 时间:针对 gp100 细胞的 T 细胞过继转移来治疗 LAM
  • 批准号:
    10682121
  • 财政年份:
    2023
  • 资助金额:
    $ 32.53万
  • 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
  • 批准号:
    10576370
  • 财政年份:
    2022
  • 资助金额:
    $ 32.53万
  • 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
  • 批准号:
    10387023
  • 财政年份:
    2022
  • 资助金额:
    $ 32.53万
  • 项目类别:
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
  • 批准号:
    10248409
  • 财政年份:
    2019
  • 资助金额:
    $ 32.53万
  • 项目类别:
A phase I clinical study of adoptive transfer of regulatory T cells (Tregs) and low-dose interleukin-2 (IL-2) for the treatment of chronic graft-versus-host disease (GVHD): gene-marking to inform rational combination therapy
调节性 T 细胞 (Treg) 和低剂量白细胞介素 2 (IL-2) 过继转移治疗慢性移植物抗宿主病 (GVHD) 的 I 期临床研究:基因标记为合理的联合治疗提供信息
  • 批准号:
    nhmrc : GNT1163111
  • 财政年份:
    2019
  • 资助金额:
    $ 32.53万
  • 项目类别:
    Project Grants
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
  • 批准号:
    10462684
  • 财政年份:
    2019
  • 资助金额:
    $ 32.53万
  • 项目类别:
Gene edited lymphoid progenitors for adoptive transfer as a treatment of primary immunodeficiency
基因编辑的淋巴祖细胞用于过继转移作为原发性免疫缺陷的治疗
  • 批准号:
    398018062
  • 财政年份:
    2018
  • 资助金额:
    $ 32.53万
  • 项目类别:
    Research Grants
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
  • 批准号:
    9308643
  • 财政年份:
    2017
  • 资助金额:
    $ 32.53万
  • 项目类别:
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
  • 批准号:
    9447149
  • 财政年份:
    2017
  • 资助金额:
    $ 32.53万
  • 项目类别:
Targeting Cancer miRNAs by Adoptive Transfer of Programmed B Lymphocytes
通过程序化 B 淋巴细胞的过继转移靶向癌症 miRNA
  • 批准号:
    8893915
  • 财政年份:
    2014
  • 资助金额:
    $ 32.53万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了